The Online Investor
Healthcare M&A image Healthcare M&A » By The Online Investor Staff, updated Fri., Mar. 29, 11:47 AM Recent mergers and acquisitions in the Healthcare M&A category.

Slide #88. Elanco, the animal health division of Eli Lilly and Company Lohmann Animal Health

Acquirer: Elanco, the animal health division of Eli Lilly and Company (NYSE:LLY)
Acquiree: Lohmann Animal Health
Details: Elanco, the animal health division of Eli Lilly and Company (NYSE:LLY), today announced an agreement to acquire Lohmann SE (Lohmann Animal Health), a privately-held company headquartered in Cuxhaven, Germany. Lohmann Animal Health is a global leader in the supply of poultry vaccines and also markets a range of feed additives. The acquisition will establish Elanco as a global poultry leader, solidify Elanco's vaccine presence, broaden Elanco's product offerings and significantly augment Elanco's vaccine manufacturing capabilities.

Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products and other therapies. Co.'s diabetes products include: Basaglar®, a long-acting human insulin analog for the treatment of diabetes; and Trajenta®, for the treatment of type 2 diabetes. Co.'s oncology products include: Alimta®, for treatment of patients with non-squamous cell histology and no epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations.

Eli Lilly SEC Filing Email Alerts Service


Open the LLY Page at The Online Investor »

Company Name: 
Lilly (Eli) & Co
Stock buyback: 
LLY buyback
Website: 
www.lilly.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding LLY: 
121
Total Market Value Held by ETFs: 
$78.45B
Total Market Capitalization: 
$739.40B
% of Market Cap. Held by ETFs: 
10.61%
 

Open the LLY Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree LLY Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (3.79 out of 4)
71st percentile
(ranked higher than approx. 71% of all stocks covered)

Analysts' Target Price:
LLY Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Healthcare M&A - Slide 88 of 100 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2024, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.